Zydus Cadila has launched its new anti-diabetic drug, Tenglyn, a generic oral version of gliptins at the most affordable price of Rs. 7 per tablet in India.
New Inexpensive Cancer Drug Launched by Cadila
Cadila Pharmaceuticals has just announced the entry of its new drug for lung cancer management. This is seen as an important development in the treatment of lung cancer.
Cadila Pharmaceuticals has just announced the entry of its new drug for lung cancer management. This is seen as an important development in the treatment of lung cancer.
‘The new anti-diabetic drug, Tenglyn offered at a price of rs.7 per tablet will be a boon for 60 million diabetic patients in India.’
"With Tenglyn we provide patients suffering from diabetes access to this advanced treatment at the most affordable cost," said Sharvil Patel, Deputy Managing Director, Zydus Cadila. Therefore, this new launch of the same drug at a cost of rs.7 will help 60 million diabetic patients economically. The cost-effective drug will also be made easily accessible all over the country. The price of Zydus is said to be one sixth of all other pharmaceutical companies.
Source-Medindia
The US Regulatory Authorities Approve Novo's New Diabetes Drug 'Tresiba'
The US Food and Drug Administration’s approval was based on the clinical trials that showed the drug, Tresiba can improve glycemic control.
The US Food and Drug Administration’s approval was based on the clinical trials that showed the drug, Tresiba can improve glycemic control.
Glenmark India Launches Teneligliptin for Management of Type 2 Diabetes
Teneligliptin is an advanced new third-generation oral anti-diabetic agent that suppresses' glucagon release and increases insulin to lower blood glucose levels.
Teneligliptin is an advanced new third-generation oral anti-diabetic agent that suppresses' glucagon release and increases insulin to lower blood glucose levels.
USFDA Halts the Launch of AstraZeneca�s Fixed-Dose Diabetes Drug for Treatment
US heath regulators stated that more clinical data were required before it could approve the combination of saxagliptin and dapagliflozin for diabetes treatment.
US heath regulators stated that more clinical data were required before it could approve the combination of saxagliptin and dapagliflozin for diabetes treatment.
